Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an updated investor presentation with additional data on the company's BHV-1300 program, a potential competitor to FcRn-targeting therapeutics such as argenx's SE (NASDAQ: ARGX) Vyvgart, Immunovant Inc's (NASDAQ: IMVT) IMVT-1402, and Janssen's (NYSE: JNJ) nipocalimab.
According to William Blair, whereas FcRn-targeting biologics work indirectly by reducing the lifespan of IgG through their action on the neonatal Fc receptor (FcRn), which typically safeguards IgG from lysosomal degradation, BHV-1300 takes a direct approach by targeting IgG itself for degradation.
This unique mechanism sets BHV-1300 apart and is believed to offer ...